Trial Profile
Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Vadadustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Akebia Therapeutics
- 28 Jul 2020 Primary endpoint (Mean change in Hb levels from pre-treatment to the end of the primary efficacy period) has been met, according to results published in the Nephrology Dialysis Transplantation
- 28 Jul 2020 Results assessing safety and efficacy of daily oral vadadustat in two clinical studies: NDD-CKD (NCT03054350) and DD-CKD (NCT03054350) in Non-dialysis dependent or dialysis-dependent Chronic kidney disorder induced anemia in Japanese participants published in the Nephrology Dialysis Transplantation
- 29 Sep 2017 Status changed from active, no longer recruiting to completed.